GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial.Study 2: Patients on the waiting list for kidney transplantation.
- Conditions
- Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantationTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-506436-33-00
- Lead Sponsor
- Bellvitge University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Patients on the RT waiting list, Over 18 years, Women of childbearing potential must use effective contraceptive measures during their participation in the study., With metabolic syndrome defined by 3 or more of the following criteria (National Cholesterol Education Program Adult Treatment Panel III guidelines (7) adjusted to the patient with chronic kidney disease: a) prediabetes determined by: ? fasting plasma glucose of 100-126 mg/dL (5.6-6.9 mmol/L), ? and/or impaired fasting glucose of <126 mg/dL (7 mmol/L) with 2-h plasma glucose after oral glucose of 140–200 mg/dL (7.8–11 mmol/L) ? and/or HbA1c 5.7-6.4%) b) obesity defined by BMI = 27 Kg/m2 c) triglycerides =150 mg/dL or under treatment d) Waist circumference greater than 101.6 cm (men) or 88.9 cm (women)
Under 18 years of age,, previously diagnosed diabetes,, Hepatic Failure, history of pancreatitis (acute or chronic),, síndrome de neoplasia endocrina múltiple tipo 2 (MEN 2), personal or family history of medullary thyroid carcinoma (MTC),, pregnant or lactating women, moderate to severe pre-existing gastroparesis.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method